Alaska Clinical Research Center
Alaska Clinical Research Center, LLC (ACRC) is an educational and research affiliate of Alaska Urological Institute, APC. It is a separate site and entity founded by a team of urologists dedicated to conducting clinical research trials in urology.
Our primary objective is to provide optimal patient care by giving patients access to a broad spectrum of treatment alternatives, and greater understanding of new therapies.
Our primary objective is to provide optimal patient care by giving patients access to a broad spectrum of treatment alternatives, and greater understanding of new therapies.
All Research Studies (on ClinicalTrials.gov)
Therapeutic Areas:
- Urology
- Urogynecology
- Urologic Oncology
- Nephrology
- Sexual Dysfunction
Our research is specialized to any of our therapeutic specialties, and encompass clinical trials in all phases of study. (Phases II, III, and IV).
- Erectile Dysfunction
- Hypogonadism
- Prostate Cancer
- Prostatitis
- Benign Prostatic Hypertrophy (BPH)
- Pyelonephritis / Urinary Tract Infections
- complicated & uncomplicated - Bladder Cancer
- Urolithiasis
- Urinary Incontinence
- Interstitial Cystitis
Our center has worked with the following:
Sponsors:
Merck, Bristol-Meyers Squibb, Eli Lilly, Active Biotech Astellas, AstraZeneca, ALZA Corporation, Amgen, Praecis Pharmaceuticals, Schering-Plough, TAP Pharmaceuticals, Uroplasty, Cellegy, Lexigen, Atrix Laboratories, Pharmacia, Abbott, Boehringer Ingelheim, Bayer, Novartis, Takeda, Millenium
Merck, Bristol-Meyers Squibb, Eli Lilly, Active Biotech Astellas, AstraZeneca, ALZA Corporation, Amgen, Praecis Pharmaceuticals, Schering-Plough, TAP Pharmaceuticals, Uroplasty, Cellegy, Lexigen, Atrix Laboratories, Pharmacia, Abbott, Boehringer Ingelheim, Bayer, Novartis, Takeda, Millenium
CRO’s:
PPD Development, Quintiles, Covance, Phoenix International, Kendle, The Phoenix, i3 Research, Inc., ILEX Oncology, Diagnostic Oncology
Browse the active studies below to learn about eligibility for patient participation.
| Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer | |
| Condition: | Prostate Cancer |
| Interventions: | Dietary Supplement: pomegranate juice; Other: placebo |
| Study of Immunotherapy to Treat Advanced Prostate Cancer | |
| Condition: | Prostate Cancer |
| Interventions: | Drug: Ipilimumab; Drug: Placebo |
| Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer | |
| Condition: | Prostatic Neoplasms |
| Interventions: | Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone |
| Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | |
| Condition: | Prostate Cancer |
| Interventions: | Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone |
| A Study in Men With Benign Prostatic Hyperplasia Eli Lilly | |
| A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH) | |
| Condition: | Benign Prostatic Hyperplasia |
| Interventions: | Drug: LY500307 Drug: Placebo |
| Febuxostat Versus Allopurinol or Placebo in Subjects With Hyperuricosuria and Calcium Oxalate Stones Takeda Global Research & Development, Inc | |
| A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to Evaluate Febuxostat in the Medical Management of Subjects With Hyperuricosuria and Calcium Oxalate Stones | |
| Condition: | Hyperuricosuria Kidney Stones |
| Interventions: | Drug: Febuxostat Drug: Allopurinol Drug: Placebo |
| Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Light Sciences Oncology | |
| A Phase 1 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy | |
| Condition: | Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms |
| Interventions: | Drug: Talaporfin sodium Procedure: Placement of device in prostate urethra Device: Transurethral illumination with light emitting diodes (Litx™ BPH Device) |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer. Active, but closed to further enrollment |
|
| Condition: | Bladder Cancer |
| Interventions: | Drug: EOquin® (Apaziquone) |
| Efficacy Study of ABR-215050 to Treat Prostate Cancer Active Biotech | |
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer |
|
| Condition: | Prostate Cancer |
| Interventions: | Drug: ABR-215050, tasquinimod Drug: Placebo |
| The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Auxilium Pharmaceuticals, Inc. | |
| Phase 3 study will start in Fall, 2010-05-10 | |
| Condition: | |
| Interventions: | |